Glizid-MV Tablet SR is a combination oral antidiabetic medication containing Voglibose (0.2 mg), Metformin (500 mg), and Gliclazide (80 mg), formulated as a sustained-release tablet to optimize glycemic control in patients with type 2 diabetes mellitus. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, thereby reducing postprandial hyperglycemia. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Gliclazide, a sulfonylurea derivative, stimulates pancreatic beta-cell insulin secretion, aiding in the reduction of fasting and postprandial blood glucose levels. The sustained-release formulation ensures a gradual and prolonged drug release, minimizing peak plasma fluctuations and reducing the risk of hypoglycemia. Glizid-MV is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes inadequately controlled by monotherapy or dual therapy. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to any component. Adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare hematologic abnormalities.